Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANCEF IN PLASTIC CONTAINER vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Perioperative prophylaxis,Urinary tract infections,Respiratory tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Off-label: Intra-amniotic infection (chorioamnionitis)
Perioperative prophylaxis,Respiratory tract infections,Urinary tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Genital infections (e.g., prostatitis, epididymitis),Off-label: Surgical prophylaxis in certain procedures
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (Cr Cl <10 m L/min); anephric patients up to 40 hours.
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (Cr Cl <10 m L/min)
Cefazolin undergoes minimal hepatic metabolism; primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion.
Cefazolin is minimally metabolized; primarily undergoes renal tubular secretion and glomerular filtration. Not significantly metabolized by cytochrome P450 enzymes.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
80-86% primarily to albumin.
80-86% bound to serum albumin
0.12-0.14 L/kg (8-14 L in adults); indicates limited extravascular distribution (primarily extracellular fluid).
0.12-0.16 L/kg; primarily in extracellular fluid
IM: 100% (complete absorption); not administered orally.
IM: ~85% (peak levels in 0.5-2 hours); IV: 100%
Cr Cl >55 m L/min: 1-2 g q8h; Cr Cl 35-54: 1-2 g q8h (caution); Cr Cl 11-34: 1-2 g q12h; Cr Cl <10: 1-2 g q24h (or 500 mg q12h).
Cr Cl 35-54 m L/min: 1-2 g every 8 hours. Cr Cl 11-34 m L/min: 1-2 g every 12 hours. Cr Cl <10 m L/min: 1-2 g every 24-48 hours. For patients on hemodialysis, administer 1-2 g after each dialysis session.
No dose adjustment required for hepatic impairment. Child-Pugh classification does not alter dosing.
No dosage adjustment required for hepatic impairment. Cefazolin is primarily renally eliminated.
Infants and children: 50-100 mg/kg/day IV/IM divided q8h. Severe infections: 100 mg/kg/day, max 6 g/day.
For children >1 month: 25-100 mg/kg/day IV divided every 6-8 hours. For severe infections: up to 100 mg/kg/day IV divided every 6-8 hours. Maximum dose: 6 g/day.
Dose based on renal function. Use lower end of dosing range due to age-related creatinine clearance decline. Monitor renal function.
Adjust dose based on renal function. Calculate Cr Cl and follow renal adjustment guidelines. No additional geriatric-specific modifications beyond renal consideration.
No FDA black box warning.
None
Hypersensitivity reactions including anaphylaxis,Pseudomembranous colitis due to Clostridium difficile,Bleeding risk due to hypoprothrombinemia (rare),Seizures with high doses in renal impairment,Superinfection with prolonged use,Drug interactions with nephrotoxic agents (e.g., aminoglycosides)
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams; caution in penicillin-allergic patients,Acute generalized exanthematous pustulosis (AGEP),Clostridioides difficile-associated diarrhea (CDAD),Seizures at high doses or in renal impairment,Nephrotoxicity (especially with aminoglycosides or loop diuretics),Hemolytic anemia (rare),Interference with glucose and protein tests,Use in renal impairment: dose adjustment required,Pregnancy category B: use only if clearly needed,Geriatric use: increased risk of adverse effects
Known hypersensitivity to cefazolin or other cephalosporins,Severe allergic reaction to penicillins (cross-sensitivity)
Hypersensitivity to cefazolin or any cephalosporin,Severe immediate hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams
Alcohol may cause disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to interference with acetaldehyde metabolism; avoid alcohol during therapy and for 48 hours after last dose. No other significant food interactions.
No specific food interactions. Avoid alcohol during therapy and for 72 hours post-treatment due to risk of disulfiram-like reaction (cefazolin has a methylthiotetrazole side chain). Patients with diabetes should account for dextrose content (5 g/100 m L) in their carbohydrate intake.
Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly needed; second and third trimester use considered safe when indicated.
Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in first trimester; use only if clearly needed.
Cefazolin is excreted into human breast milk in low concentrations (M/P ratio approximately 0.02-0.16). Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal disturbances and sensitization.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.5). Considered compatible with breastfeeding; monitor for potential gastrointestinal effects in the infant.
No specific dose adjustment recommended in pregnancy. Physiologic increases in plasma volume and renal clearance may theoretically reduce cefazolin concentrations, but standard dosing regimens are considered adequate for prophylaxis and treatment.
Increased glomerular filtration rate during pregnancy may require higher doses or more frequent dosing to achieve therapeutic concentrations; specific dose adjustment not established; monitor clinical response.
First-generation cephalosporin; administer IV/IM; adjust dose in renal impairment (Cr Cl <55 m L/min); monitor for hypersensitivity (cross-reactivity in 10% of penicillin-allergic patients); use for surgical prophylaxis (administer within 60 minutes before incision); drug of choice for MSSA infections; tissue penetration good, but CNS penetration limited unless meninges inflamed.
For surgical prophylaxis, administer within 60 minutes before incision. Use extended infusion (over 1-2 hours) for critically ill patients to optimize pharmacokinetic/pharmacodynamic target attainment. Monitor renal function given cefazolin excretion; adjust dose for Cr Cl <55 m L/min. Avoid in patients with immediate-type hypersensitivity to penicillins (10% cross-reactivity risk). In obese patients (BMI ≥40 kg/m²), consider doubling the standard dose (2 g IV) for adequate tissue penetration.
Take exactly as prescribed; complete full course even if feeling better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling) immediately.,Avoid alcohol during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction.,Inform healthcare provider if you have kidney disease, history of colitis, or are pregnant/breastfeeding.,Diarrhea may occur; report if severe, watery, or bloody (possible C. diff infection).
Complete the full course of antibiotics as prescribed, even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling of face or throat) to your healthcare provider immediately.,If you are diabetic, note that each 1% dextrose solution provides 3.4 kcal/g; monitor blood glucose levels closely.,The medication is given intravenously; ensure the IV site is clean and free from redness, swelling, or pain.,Avoid alcohol during treatment and for at least 72 hours after the last dose to prevent disulfiram-like reactions (flushing, nausea, vomiting).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANCEF IN PLASTIC CONTAINER vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ANCEF IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANCEF IN PLASTIC CONTAINER and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANCEF IN PLASTIC CONTAINER is: 1-2 g IV/IM every 8 hours. Maximum 12 g/day.. The standard adult dose of ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is: For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANCEF IN PLASTIC CONTAINER and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANCEF IN PLASTIC CONTAINER is classified as Category C. Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.